Diligence the reading before you fund it
A funding decision turns on whether the claims actually read on real products, and how defensibly. ClaimHit screens the asset against the live market, ranks what it finds by how strong the evidence really is, and shows the excerpt behind every line, including, deliberately, the limitations it could not evidence.
- —Evidence of use is the question that decides whether a case is fundable, and the most expensive thing to produce before you have committed a dollar.
- —A rosy infringement read that buries its weak limitations is worse than no read. The gap you did not see is the one opposing counsel will.
- —Screening a pipeline of candidate cases by hand does not scale to real deal flow.
What ClaimHit does about it
Ranked by what was proven
Targets are ordered by how much public evidence backs each one, with the sources listed. Anything that could not be confirmed is dropped, so the strong cases separate from the thin ones.
The weak limitation, named
Every claim is mapped element by element. PARTIAL is never rounded up to FULL and an undocumented limitation is reported NONE, so you see the vulnerability before you underwrite it rather than after.
Screen the deal flow
Run candidate assets through the same pipeline, so the comparison across cases is like for like rather than a sample judged by feel.
Every line traceable
Citations are validated against the passage they claim to come from; a plausible reference that does not contain the support is rejected, not shipped. The evidence trail is one your own counsel can check.
Every result has to earn it. Candidates come from several models, live web search, forward citations and the registries for the field, but breadth only widens the net. Each one is still checked against real, citable evidence. See how →
ClaimHit produces preliminary research, not a merits opinion or legal advice. The point is to reach the diligence conversation with the evidence, and the gaps, already on the table.
See a real Hit Report first.
A complete ClaimHit output on a published patent: the companies and products it reaches, the sources that confirmed each one, and a Hit Chart on the strongest hit. One email, no account.
Or watch a patent: we tell you when a new company appears for it.
Thirty minutes, your patent, your questions.
Bring a patent number. We run it live, walk through the results and the Hit Chart, and answer whatever your team needs to know before it decides.
Pick a time that suits. No preparation needed beyond the patent number.
See who is using your patent.
The pilot is one patent: the full product search and one Hit Chart, with a 30-day money-back guarantee. No subscription, no card on file after that.